Anthonius de Boer.

In conclusion, we investigated the usage of a dosing algorithm that included both pharmacogenetic and clinical factors, in comparison with an algorithm that included just scientific factors, for the initiation of treatment with acenocoumarol or phenprocoumon. There is no significant difference between the two dosing-algorithm groupings in the primary outcome of time in the therapeutic INR range during the initial 12 weeks of treatment.. Talitha We. Verhoef, M.Sc., Georgia Ragia, Ph.D., Anthonius de Boer, M.D., Ph.D., Rita Barallon, Ph.D., Genovefa Kolovou, M.D., Ph.D., Vana Kolovou, M.Sc., Stavros Konstantinides, M.D., Ph.D., Saskia Le Cessie, Ph.D., Efstratios Maltezos, M.D., Ph.D., Felix J.M. Van der Meer, M.D., Ph.D., William K.Express Scripts David Whitrap, senior director of corporate communications for Express Scripts, told Pharmacy Occasions that the ongoing organization will not segment its individual business units, but he pointed to a list made by Adam Fein, president of Pembroke Consulting and writer of DrugChannels.com. On that list, Express Scripts was rated third for 2014, with $38 billion in income from prescription sales.